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Background: Glucocorticoids (GCS) remain one of the mainstay treatments in the management of ulcerative colitis
(UC) but up to a third of patients will ultimately fail to respond and progress to a more severe and difficult to
manage disease state. Previous clinical studies suggest that the Toll-Like Receptor 9 (TLR9) agonist DIMS0150 not
only induces production of key anti-inflammatory cytokines as IL-10 but interestingly also enhances steroid sensitivity
in steroid refractory UC patients. We investigated, in the context of a clinical study, whether a pre-selection of steroid
response genes could identify steroid refractory UC subjects most likely to respond to DIMS0150 treatment.
Methods: In a non-interventional pilot study, blood from steroid refractory UC patients and healthy volunteers was
taken and thirty-four previously described steroid response genes were analysed by real time PCR analysis. To establish
clinical utility of the identified biomarkers, a placebo controlled, randomized, double blinded study in active steroid
dependent and steroid resistant UC patients on concomitant steroid therapies was used (EudraCT number:
2006-001846-15).
Results: We identified three potential biomarkers CD163, TSP-1 and IL-1RII whose response to steroids was significantly
enhanced when DIMS0150 was applied. Thirty-four subjects were randomized to receive a single rectal administration
of placebo or 30 mg of DIMS0150. Blood derived PBMCs were obtained prior to dosing and assayed for evidence of a
steroid enhancing effect following steroid incubation in the presence of DIMS0150. Comparison to established steroid
sensitivity marker IL-6 confirmed that clinical responders are steroid refractory UC patients. Upon study completion and
un-blinding, the biomarker assay correctly predicted a clinical response in over 90% of the patients.
Conclusion: Using specific steroid response biomarkers, GCS refractory UC patients most likely to benefit from
DIMS0150 treatment could be identified and illustrates the usefulness of a personalized treatment approach.
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Ulcerative colitis (UC) is a disease characterised by
chronic inflammation of the rectal and colonic mucosa.
The medical management of UC is divided into treatment
of active disease and maintenance of remission. The treat-
ment of patients with UC aims to reduce inflammation
and promote colon healing and mucosal recovery. In the
majority of cases the disease may be controlled with* Correspondence: petra.stein@indexpharma.com
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article, unless otherwise stated.conventional drugs including sulphasalazine (SASP), 5-
aminosalicylic acid (5-ASA) and glucocorticosteroids
(GCS) [1,2]. GCS are one of the mainstay treatments in
the management of inflammatory bowel disease (IBD).
GCS are potent anti-inflammatory agents widely used for
the suppression of inflammation in chronic diseases such
as asthma, rheumatoid arthritis, IBD and autoimmune
diseases [3]. However, 20-50% of IBD patients will fail to
respond to steroid therapy [4] resulting often in a more
difficult to manage disease course. Failure to respond to
GCS therapy is an indication for potential surgical inter-
vention although immunomodulatory agents such astral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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inhibitors have demonstrated some effectiveness at redu-
cing colectomy rates on a short-term basis [5,6].
DNA based immunomodulatory sequence (DIMS0150)
is a single stranded partially modified synthetic oligo-
nucleotide of 19 bases in length. The drug functions as
an immunomodulator by activating the Toll-Like Recep-
tor 9 (TLR9) present in immune cells such as B-cells,
macrophages and plasmacytoid dendritic cells (pDCs)
that are found in abundance on mucosal surfaces such
as the colonic mucosa. Through rectal administration of
DIMS0150 in the form of an enema, the agent comes in
direct contact with a large number of target cells thereby
ensuring a robust immunomodulatory response. Activa-
tion of TLR9 by DIMS0150 results in the local production
of potent anti-inflammatory cytokines such as IL-10 and
type I interferons that have also interestingly been shown
to increase steroid sensitivity in cells derived from steroid-
resistant UC patients [7] and human monocytes [8].
Results from two previous clinical studies in UC pa-
tients treated with a single rectal dose of DIMS0150
have indicated that steroid refractory UC patients benefit
from the treatment. In the first clinical study, a single
dose of DIMS0150 was given to steroid unresponsive
IBD patients on concomitant steroid therapies [9]. The
study illustrated that both single dose levels used (3 mg
and 30 mg) were effective in inducing a clinical re-
sponse. After one week five out of seven patients (70%)
that received active treatment had a clinical response
and two have remained, after more than 8 years, in GCS
free remission. One of four patients receiving placebo
responded but in a transient manner.
A larger phase II study evaluated the ability of
DIMS0150 at four dose levels (0.3, 3, 30 and 100 mg)
administered as a single rectal dose to induce clinical re-
mission in 151 patients with mild or moderately active
UC compared to placebo. No significant benefit was
demonstrated at any dose level suggesting that the lack
of efficacy was possibly due to the different patient tar-
get group (data not published). The target groups of
these studies differed in two ways, firstly the second trial
was conducted in less severe UC patients and secondly
concomitant steroid therapy was an exclusion criteria.
To investigate whether the effect of DIMS0150 in the
first study could be linked to steroid sensitivity, we
screened 34 known steroid response genes in an in vitro
assay. Additionally, to be able to re-affirm whether ster-
oid refractory UC subjects on concomitant steroid ther-
apies are the relevant target group or whether the
combination of DIMS0150 and steroid therapy is
needed, a phase IIa proof of concept (PoC) study was
conducted in steroid dependent or steroid resistant UC
patients on concomitant steroid therapies addressing
DIMS0150 at a single dose level of 30 mg.According to European Crohn’s and Colitis organisa-
tion (ECCO) guidelines, the definition of steroid resist-
ance is a failure to respond to 0.75 mg/Kg body weight
intravenous administered steroids given over 3 to 5 days
[10]. Likewise, steroid dependency is defined as the in-
ability to reduce steroid usage below 10 mg/day without
recurrent active disease. We reasoned that to determine
the clinical picture of steroid sensitivity by these means
would greatly impact the rate of inclusion into the PoC
study with many patients opting not to undergo these
demanding procedures. Consequently, we employed the
use interleukin 6 (IL-6) that has gained significant recog-
nition as a suitable biomarker for determining the steroid
sensitivity status of a subject in published research as well
as its use in human clinical studies addressing steroid re-
sistant disorders such as asthma and ulcerative colitis
[11-14]. This PoC study also enabled us to evaluate the
suitability of potential biomarkers for DIMS0150 whether
they could be used to predict a clinical response.
The results from this PoC phase IIa study indicate that
GCS refractory patients on concomitant GCS therapy re-
spond more favourably to a single dose of DIMS0150 and
the utility of the biomarkers CD163, TSP-1 and IL-6 in
confirming the right target group and predicting a most
likely response to DIMS0150 could be demonstrated.
Using the biomarkers we could also demonstrate a steroid
re-sensitizing effect in vivo following DIMS0150 treatment
in a case report from a named patient basis program and
confirm that after treatment with DIMS0150, GCS can be
used to successfully treat a new disease flare in a patient.
Methods
Study design and patient population
Identification of potential steroid response biomarkers
A study including 9 steroid resistant active UC patients
and 9 healthy volunteers (mean age of 44.7 and 44.3,
female to male ratio of 2:7 and 6:3, 9 Caucasians and 8
Caucasians plus one Latin American, respectively) was
performed to donate blood at one occasion in one study
centre in Stockholm, Sweden.
Proof of concept (PoC) phase IIa study (EudraCT number:
2006-001846-15)
The study was placebo controlled, randomized, double-
blinded and conducted in Sweden and Russia in 17 study
centres. Steroid resistant or steroid dependent patients
(Intention-To-Treat population ITT = 34) on a stable
and tolerable steroid dose of at least 5 mg/day for
2 weeks with mild to moderate UC with DAI score [2]
of 6 – 11 at screening visit were blindly allocated to ac-
tive treatment (DIMS0150) or placebo in a 2:1 ratio
((ITT = 22) versus (ITT = 12) respectively). Concomitant
stable treatment with 5-ASA or SASP was allowed dur-
ing the study period but patients treated with anti-TNFα
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was given as a single 50 mL rectal enema consisting of
30 mg of DIMS0150 in sterile water or sterile water only
in case of placebo. Primary objective of the study was to
evaluate clinical response compared to placebo, second-
ary objectives included safety and tolerability as well as
evaluation of biomarkers in comparison to the steroid
sensitivity marker IL-6. Baseline characteristics of the
patients are outlined in Table 1. The study started in
January 2007 and was terminated early in April 2009 be-
cause it was judged that allowing all subjects to complete
all scheduled visits would not provide additional meaning-
ful data in lieu of the primary endpoint.
Named patient-based treatment example
One chronic active treatment refractory UC patient (male,
50 years, pancolitis, Caucasian) was treated three times with





















Number of subjects taking glucocorticoids medication during the study







Steroids medication (PT) that occur more than once during the study period will be
Percentages calculated for the number of subjects in the safety population by treatStudy drug
DIMS0150 is a fully synthetic oligodeoxynucleotide with
the sequence 5′-G*G*A*ACA GTT CGT CCA T*G*G*C-
3′ where (*) indicates phosphorothioate linkages, produced
by Avecia (Milford, USA) and prepared as study drug by
Apoteksbolaget AB, Production & Laboratory, Umeå,
Sweden. The randomisation code was produced by a
computer-generated procedure, which used the method of
randomly permuted blocks. Double-blinding against water
was accomplished by giving all study products identical
appearance, packaging and labelling.
Blood collection and RNA isolation for IP-10 expression
analysis
Whole blood (5 mL) from 26 patients of the PoC study
(all patients included after Amendment 5 of original
protocol) was collected in PAXtubes (PreAnalytiX,
Hombrechtikon, Switzerland) just before drug administrationconcept phase IIa study
DIMS0150 (n = 22) Placebo (n = 12)
le (%) 12 (54.55) 6 (50.00)
ale (%) 10 (45.45) 6 (50.00)
casian 22 (100.00) 12 (100.00)
an (SD) 41.3 (14.96) 39.7 (12.37)
, Max 23.0, 72.0 22.0, 56.0
DIMS0150 (n = 22) Placebo (n = 12)
16 7
sing 6 5
an (SD) 916.1 (871.85) 1760.6 (806.71)
n, Max) (154.0, 3555.0) (922.0, 3003.0)
22 12
sing 0 0
an (SD) 7.9 (1.19) 7.9 (1.56)
n, Max) 7.0, 10.0 6.0, 11.0
ond splenic flexure 3 (13.64%) 2 (16.67%)
to splenic flexure 10 (45.45%) 6 (50.00%)
to sigmoid descending junction 7 (31.82%) 3 (25.00%)
to recto-sigmoid junction 1 (4.55%) 1 (8.33%)
t known 1 (4.55%) 0 (0.00%)
20 (90.91%) 11 (91.67%)
mber of steroid medications (PT) 3
enoside 2 (9.09%)
dnisolone sodium phosphate 1 (4.55%)
mber of steroid medications (PT) 21 12
rocortisone 1 (4.55%) 1 (8.33%)
thylprednisolone 1 (4.55%) 1 (8.33%)
dnisolone 19 (86.36%) 10 (83.33%)
counted only once within a subject.
ment group.
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the manufacturer’s guidelines using PAXgene Blood RNA
Kit (Qiagen, Hilden, Germany).
Blood collection and PBMC isolation and stimulation
From 32 patients of the PoC study, 30 mL blood was
collected in sodium heparin tubes (Venoject®, Teruma
Sweden AB) and peripheral blood mononuclear cells
(PBMC) isolated 24 hrs after collection by density gradi-
ent centrifugation using Ficoll-Paque Plus (Pharmacia
Biotech, Stockholm, Sweden). PBMCs were washed three
times in buffered saline solution, and resuspended in
complete RPMI 1640 medium (Sigma, St. Louis, USA).
PBMCs were seeded in 96 well plates (0.5 x 106 cells/
well), cells stimulated for 48 hrs with DIMS0150 (25 μM
or 100 μM) in the presence or absence of Dexametha-
sone (10-6, 10−8, 10−10 M; Sigma). Cell supernatant was
collected and kept at −20°C for cytokine analysis. The
cells were covered with 50 μl/well of RLT-lysis buffer
(Qiagen) containing 1% of β-mercaptoethanol and kept
at −20°C for mRNA isolation.
Cytokine analysis
IFN-γ, IL-6, IL-10, IP-10, and TNF-α were measured
using cytometric bead array (CBA) flex kit (Becton Dick-
inson) according to the manufacturer’s instructions on a
FACSArray flow cytometer using FCAP Array software
(Becton Dickinson, New Jersey, USA). IFN-α was ana-
lyzed using human IFN-α Multi-subtype ELISA kit (PBL,
Biomedical Laboratories, New Jersey, USA) and IFN-β
was detected with human IFN-β ELISA kit (Fujirebio
INC., Tokyo, Japan) according to the manufacturer’s
instructions.
Biomarker analysis
RNA isolation was performed using Qiagen RNeasy
RNA isolation kit and Qiacube (Qiagen) according to
manufacturer’s guidelines.
For first strand cDNA synthesis, 0.3-1.0 μg of total
RNA/sample and 10pM of the Oligo-dT-primer (5′-
dT20NV-3′) was taken. The reactions were performed
using Superscript II according to the manufacture’s
guidelines (Invitrogen, Carlsbad, USA).
Real-time PCR (qPCR) was performed on an ABI 7500
Real-Time PCR system using Power SYBR®Green PCR Kit
according to the manufacture’s guidelines (Applied Biosys-
tems). Reactions were performed in triplicates using 1 μl
1:10 diluted cDNA per reaction and qPCR data were ana-
lyzed using relative quantification via 2-ΔΔCt method (SDS
1.3 software, Applied Biosystems, Foster City, USA) and
γ-actin as internal control (Table 2). Gamma-actin was
chosen because it showed consistent expression in stimu-
lated and non-stimulated PBMCs and can be employed in
the same cDNA dilution as the target genes.Data analysis and statistics
Data analysis and graphing was performed in Microsoft
Office EXCEL 2007 and GraphPad Prism 4.0c. The class
membership analysis [16] was performed at Statistika
Forskningsgruppen Stockholm, Sweden using STATA®
(StataCorp LP, Texas, USA). All statistical analyses were
performed in a 95% confidence interval.
Ethics statement
Blood samples from 9 steroid resistant UC patients and
9 healthy volunteers were obtained with ethical app-
roval from EPN (Regionala Etiska Prövningsnämnden,
Stockholm, Sweden numbers 2005/1351-31/4 and 2005/
1183-31/4 respectively).
The phase IIa study (EudraCT number: 2006-001846-
15) was reviewed and approved by regional Independent
Ethics Committees (IECs) and by the medical authorities
in each country prior to inclusion of patients.
Named patient basis treatment was performed under
the responsibility of the treating physician and with ap-
proval of the local ethic committee (Ethik-Komission der
Ärztekammer Westfalen-Lippe und der Medizinischen
Fakultät der Westfälischen Wilhelms-Universität Műn-
ster, reference number 2008-360-f-S).
All patients had received written and verbal informa-
tion concerning the study/treatment and signed an in-
formed consent. From the named patient basis treated
patient an additional written consent was obtained
allowing the publication of individual clinical data.
Results
DIMS0150 induces cytokines having a role in steroid
sensitivity
DIMS0150 is a fully synthetic oligodeoxynucleotide and
its mode of action is thought to be triggered by the
interaction with TLR9, which stimulates the production
of specific chemokines and cytokines from mucosal im-
mune cells, such as B-cells, macrophages and pDCs. To
determine which cytokines are produced, in vitro studies
were performed on PBMCs isolated from healthy subjects
and stimulated with DIMS0150. The results demon-
strated a pronounced production of anti-inflammatory
cytokines like IL-10 and type I interferons and the che-
mokine IP-10 (Figure 1). Interestingly, both IL-10 and
IFNs have been previously described as being able to
modulate the steroid sensitivity of specific cells and
thereby improved the response to steroids in steroid re-
sistant individuals [7,8,17,18].
Steroid response genes show steroid enhancing effect of
DIMS0150
Through the induction of these steroid sensitizing cyto-
kines by DIMS0150, it was speculated that DIMS0150
can sensitize to steroids and therefore was beneficial in
Table 2 Primer information qPCR
Gene ID # Forward primer sequence Reverse primer sequence
γ-actin 71 5′-TGCCGACAGGATGCAGAA-3′ 5′-GGGTGCGATGATCTTGATCTTC-3′
IP-10 3627 5′-TGAAAAAGAAGGGTGAGAAGAGATG-3′ 5′-TTTAGACCTTTCCTTGCTAACTGCTT-3′
CD163 9332 5′-GCTGCAGTGAATTGCACAGATAT-3′ 5′-CGGGATGAGCGACCTGTT-3′
TSP-1 7057 5′-CGGGATGAGCGACCTGTT-3′ 5′-GTACTGAACTCCGTTGTGATAGCATAG-3′
IL-1RII 7850 5′-TCACTAGGAGTATTGAGCTACGCATC-3′ 5′-ATTGTCAGTCTTGACCCCAGAGA-3′
IL-6 3569 5′-AGCCCTGAGAAAGGAGACATGTA-3′ 5′-TCTGCCAGTGCCTCTTTGCT-3′
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concomitant steroid dosage. In order to investigate if
DIMS0150 has indeed the ability to increase the steroid
sensitivity of a patient, it was necessary to first identify
suitable steroid response biomarkers. For this purpose
blood samples derived from steroid resistant UC patients
(n = 9) were obtained and a panel of 34 potential steroid
response genes [4,17,19-32] were screened in compari-
son to healthy individuals (n = 9) (Table 3). As described
in Galon et al., isolated PBMCs from steroid resistant
patients and healthy volunteers were stimulated with
three doses of Dexamethasone (10−10 M, 10−8 M, 10−6 M)
and incubated with or without DIMS0150 (25 μM and
100 μM). To be selected as a potential biomarker for the
sensitizing effect of DIMS0150, four criteria had to be ful-
filled. Firstly, the individual variation in the expression of
a gene in healthy volunteers should be minimal. Secondly,
the effect of Dexamethasone stimulation should produce a
reliable induction or repression. Thirdly, to discriminate
between steroid resistance and normal sensitivity, aFigure 1 Cytokine production by human PBMCs stimulated with DIM
with 0.5 μM or 10 μM of DIMS0150 for 48 hrs. Cell culture supernatants we
TNF-α) and ELISA (IFN-α and IFN-β). As control, cytokine levels obtained fro
values. Protein levels [pg/ml] are presented as mean values and SEM bars.biomarker must demonstrate an impaired steroid re-
sponse in the resistant group compared to healthy. Lastly,
the biomarker should show a clear synergistic enhance-
ment after co-stimulation with DIMS0150. Three genes
(CD163, TSP-1 and IL-1RII) could be identified on the
basis of their elevated expression levels when stimulated
with DIMS0150 and Dexamethasone (Figure 2). When
PBMCs derived from steroid resistant UC patients were
stimulated with Dexamethasone, the level of CD163 in-
duction was significantly lower compared to healthy controls
suggesting a reduced level of steroid sensitivity. However,
addition of DIMS0150 to the Dexamethasone treatment pro-
duced a significant enhancement of CD163 mRNA levels
suggesting that DIMS0150 had restored the sensitivity of the
PBMCs to Dexamethasone to a level approaching that of
healthy controls (Figure 2A). By contrast, treatment of
PMBCs with DIMS0150 alone had no effect. A similar rela-
tionship could be demonstrated for TSP-1 (Figure 2B) and
Il-1RII (Figure 2C) with a clear reduced response to the ap-
plied Dexamethasone that could be significantly reversedS0150. Human PBMC from healthy volunteers (n = 5) were stimulated
re collected and analysed using CBA flex (IFN-γ, IL-6, IL-10, IP-10, and
m PBMC incubated with medium alone were subtracted from all the
Table 3 List of steroid response genes screened in biomarker assay
Gene Name Gene ID Reference Sreening result
TLR9 Toll-like receptor 9 54106 19, 20 3
TSP-1 Thrombospondin-1 7057 19 5
TSP-2 Thrombospondin-2 7058 19 1
IDO Indoleamine 2,3-dioxygenase 1 3620 19 4
MARCO Macrophage receptor with collagenous structure 8685 19 4
IL-1β Interleukin 1, beta 3553 19 1
IL-1RI Interleukin-1 receptor type 1 3554 19 4
IL-1RII Interleukin-1 receptor type 2 7850 19, 21 5
IL-1Rα Interleukin-1 receptor antagonist 3557 19 3
IL-1RAP IL-1 receptor accessory protein 3556 20 3
IL-7Rα Interleukin 7 receptor, alpha 3575 19 1
IL-13Rα2 Interleukin-13 receptor subunit, alpha 2 3598 19 1
CD163 Antigen CD163 9332 19 5
GZMA Granzyme 1, serine esterase 3 3001 19 4
GILZ Glucocorticoid-induced leucine zipper 1831 19 1
CD49D Antigen CD49D; integrin alpha 4 3676 19 1
GRα Glucocorticoid nuclear receptor, isoform alpha 2908 5, 20 3
GRβ Glucocorticoid nuclear receptor, isoform beta 2908 19, 20 3
GRγ Glucocorticoid nuclear receptor, isoform gamma 2908 20 3
HSP90α Heat shock protein HSP 90, alpha 3320 22 2
HSP90β Heat shock protein HSP 90, beta 3326 22 2
UGT2 UDP glucuronosyltransferase 2 7362 23 2
IRS-1 Insulin receptor substrate 1 3667 23 4
FoxP3 Forkhead box protein P3 50943 24 4
CFL1 Cofilin 1 1072 25 1
HDAC2 Histone deacetylase 2 3066 26 1
IGFBP2 Insulin-like growth factor binding protein 2 3485 27 1
MDR1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 5243 4 1
VitD3R Vitamin D (1,25- dihydroxyvitamin D3) receptor 7421 17 1
FKBP51 FK506 binding protein 5 2289 28 3
GROα Growth-regulated gene-alpha 2919 29 3
VEGFA Vascular endothelial growth factor 7422 30 2
SGK Serum- and glucocorticoid-inducible protein kinase 6446 31 1
IFNγR1 Interferon gamma receptor 1 3459 32 1
(1)Excluded because of too high individual variability in healthy volunteers.
(2)Excluded because Dexamethasone (Dex) response in healthy volunteers was not reliable.
(3)Excluded because difference in Dex response between steroid resistant patients and healthy volunteers was not reliable.
(4)Excluded because of missing or not reliable synergistic effect when stimulated with Dex and DIMS0150.
(5)Selected as potential biomarker because all four criteria were fulfilled (see text).
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genes imply that DIMS0150 has steroid re-sensitizing activity
and could potentially be used as biomarkers to identify sub-
jects of reduced steroid sensitivity. Perhaps more import-
antly, they could also function as potential surrogate markers
of a clinical response allowing identification of those subjects
most likely to respond to DIMS0150 treatment.DIMS0150 provides clinical benefit in patients with UC on
concomitant steroid therapy
To investigate the clinical usefulness of these steroid sen-
sitivity biomarkers as surrogate markers for DIMS0150, a
PoC phase IIa study conducted to confirm the target
group of DIMS0150 was used. The objective of this study
was to evaluate the clinical response following single dose
Figure 2 DIMS0150 can enhance in vitro steroid sensitivity in steroid resistant UC patients. PBMCs from 9 steroid resistant UC patients and
from 9 healthy volunteers were incubated for 48 hrs in the absence or presence of Dexamethasone and/or DIMS0150 and the expression levels
analysed for (A) CD163, (B) TSP-1 and (C) IL-1RII. The P-values between two groups were calculated using unpaired t-test, the P-values inside a
group were calculated using paired t-test.
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resistant or steroid dependent UC patients on concomi-
tant steroid medication. Clinical responders were defined
as patients showing a decrease in the Disease Activity
Index (DAI) [2] score of ≥3 points from baseline and the
difference in the number of responders in the two groups(active versus placebo) was assessed at two different time
points with two further follow-up visits to gain informa-
tion on next relapses and the safety profile (Figure 3). The
results from this study confirmed the efficacy observations
made in the first clinical study in that a notable improve-
ment of clinical symptoms was observed one week after a
Figure 3 Design of the explorative phase IIa study. Steroid
resistant and steroid dependent UC patients were included in a
placebo controlled double-blind study to re-affirm the target group
for the treatment with DIMS0150 and for evaluation of biomarkers.
(Black arrow) efficacy measure time point, (dashed arrow) follow-up
time point.
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also be shown that only those patients that had a clinical
response following DIMS0150 treatment experienced a




Week 1 (wk1) 2
Week 4 (wk4) 4
Sustained clinical response:













Wk4 and wk12 0/
Clinical response paralleled with histological remission
Wk4 0/
1defined as DAI score decrease of at least 3 points from baseline.
2defined as a total DAI score of 2 points or lower, with no individual sub-score exce
3defined as histology score decrease of at least 3 points from baseline.
4defined as histology score decrease to a score of zero.
No wk24 data of patients with sustained remission available.
(ITT) Intention-To-Treat; P values calculated with Fisher’s Exact Test for response/remremission was paralleled with mucosal healing (histo-
logical remission [33]). DIMS0150 demonstrated a very
favourable safety profile with no significant differences in
adverse events between the treatment and placebo groups.Evidence of TLR9 activation by DIMS0150
Interferon-γ induced protein 10 (IP-10) is known to be a
sensitive in vivo marker for the pharmacological activity
of CpG containing oligonucleotides that act through the
TLR9 pathway [34-36]. As DIMS0150 is capable of indu-
cing IP-10 in vitro (see Figure 1), we set out to measure
IP-10 in vivo as evidence of the TLR9 stimulation.
Whole blood samples from 26 patients were obtained in
order to monitor the expression of IP-10 mRNA (see
Figure 3). Once the clinical study had been un-blinded,
the IP-10 expression data were compared in terms of
whom received study drug or placebo. The qPCR ana-
lysis indicated that IP-10 expression was significantly in-
creased in the DIMS0150 treatment group 4 hrs after
dosing, whereas no change in IP-10 expression was ob-
served in the placebo group (Figure 4).IIa study
T population (n = 34)
acebo (n = 12) DIMS0150 (n = 22) P value
(17%) 7 (32%) 0.43
(33%) 9 (41%) 0.71
12 (0%) 6/22 (27%) 0.06
(8%) 2 (9%) 1.0
(0%) 3 (13%) 0.27
12 (0%) 2/22 (9%) 0.18
(0%) 6 (27%) 0.06
8 (0%) 3/16 (19%) 0.2
(0%) 6 (27%) 0.06
8 (0%) 3/16 (19%) 0.2
4 (0%) 4/9 (44%) 0.22
eding 1 point.
ission rates.
Figure 4 Pharmacological activity of DIMS0150. In the explorative phase IIa study, whole blood was collected before and 4 hrs after
DIMS0150 treatment and the levels of IP-10 mRNA measured through qPCR. The P-value was calculated between placebo and DIMS0150 treated
group using unpaired t-test.
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sensitivity
Blood derived PBMCs were isolated from 32 patients
from the PoC phase IIa study at the time of screening,
treated in vitro with Dexamethasone and/or DIMS0150
for 48 hrs and the expression levels of CD163, TSP-1,
IL-1RII and IL-6 determined through qPCR analysis. In
response to stimuli, levels of IL-6 are increased and the
degree of suppression by GCS is indicative of the steroid
sensitivity. Indeed, the ability of GCS to suppress the
levels of induced IL-6 appears to be an accepted meas-
ure of steroid sensitivity as there appears to be a robust
correlation with the clinical picture of steroid resistance
[11,13,14]. The use of IL-6 circumvents the need for pa-
tients to undergo what are otherwise uncomfortable
treatments such as taking high levels of steroid i.v. over
a period of 5 days to determine the subjects’ steroid
sensitivity.
Prior to un-blinding, two types of responses in the IL-
6 biomarker assay were observed (Figure 5A). One
group appeared to behave like healthy controls demon-
strating a strong reduction of the induced levels of IL-6
following Dexamethasone incubation (steroid sensitive
patients), whereas no suppression of IL-6 was noted in
the other group (steroid resistant patients). Also with
the biomarkers CD163, TSP-1 and IL-1RII, two differing
groups of steroid responses could be observed as shown
by the example of CD163 (Figure 5B). One group ap-
peared to behave like healthy controls when stimulated
with Dexamethasone or Dexamethasone combined with
DIMS0150 suggesting that these patients had a compar-
able steroid sensitivity. By contrast, the other group had
a significant reduction in the level of Dexamethasone-
induced CD163 expression compared to healthy con-
trols. Furthermore, this reduced response could be sig-
nificantly enhanced by the addition of DIMS0150
confirming previous in vitro observations that DIMS0150
is able to restore steroid sensitivity in steroid resistantpatients suggesting that the patient group with reduced
steroid response are steroid refractory.
Both biomarkers, IL-6 and CD163, were able to iden-
tify the same two groups, namely patients being resistant
to steroids and those being similar to healthy controls
and segregate between steroid refractory and sensitive
patients. TSP-1 as well as IL-1RII could also segregate
between two differing steroid sensitivity groups whereby
the correlation between IL-6 and CD163 or TSP-1 was
in both cases over 71% and IL-1RII showed only a cor-
relation of about 45% (data not shown).Biomarkers have high potential in predicting clinical
response to DIMS0150
Upon PoC phase IIa completion, we determined whether
there was a correlation between patients showing a re-
duced steroid sensitivity in the biomarker assay before
treatment and clinical response. In other words, is steroid
resistance a pre-requisite for a response to DIMS0150 and
could this be used as a predictor. Of equal interest was to
determine whether those subjects that had previously
demonstrated in the biomarker assay that DIMS0150
could restore their in vitro steroid sensitivity had an actual
clinical response to DIMS0150.
For this purpose, classification analyses were performed
using the raw data from the relative quantification analysis of
the performed in vitro assay compared to the clinical out-
come. From the 22 patients receiving DIMS0150, 10 patients
had a clinical response at week 1 and/or week 4 and 12 pa-
tients had no clinical response either at week 1 or at week 4.
For all the statistical analysis the first group of patients were
classified as clinical responders and the second group as clin-
ical non-responders. Table 5 provides values for area under
the ROC (Receiver operating characteristics) curves (AUC)
when using each of the markers CD163, TSP-1 and IL-6
separately and in combination at two concentrations of
Dexamethasone (10−8 and 10−6 M) and 25 μMDIMS0150.
Figure 5 Biomarkers detect two subgroups of patients in the phase IIa study. Whole blood was collected at screening from 32 patients
and PBMC incubated for 48 hrs in the absence or presence of Dexamethasone and/or DIMS0150. The expression levels for (A) IL-6 and (B) CD163
were analysed and the data divided into two groups using arbitrary cut-offs. In case of IL-6, one patient had an outlying IL-6 stimulation (>100
fold) and was removed from the analysis. The P-values between two groups were calculated using unpaired t-test, the P-values inside a group
were calculated using paired t-test.
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CD163, TSP-1 and IL-6, had singularly high predictive
potential for a clinical response in subjects that demon-
strated reduced levels of steroid sensitivity suggesting
that refractory patients are more likely to respond to
DIMS0150. Additionally, CD163 and TSP-1 demon-
strated a strong positive correlation between subjects
where a restored in vitro steroid sensitivity was observed
upon DIMS0150 incubation and clinical response. IL-
1RII had less discriminative potential due to strong pa-
tient variations (data not shown). However, the highestprediction values were achieved when all three bio-
markers CD163, TSP-1 and IL-6 were considered for
steroid resistance and, taking into account restoration of
steroid sensitivity as determined by CD163 and TSP-1.
This gave an AUC of 0.98 with 10−6 M Dexamethasone
and 25 μM DIMS0150 in contrast to an AUC of 0.83 for
IL-6 alone at the same concentrations (Table 5, see also
Figure 5A).
For graphical illustration, the principal components
(pc) were calculated from data derived from CD163,
TSP-1 and IL-6 and the pc1/pc2 distribution plotted,
Table 5 Area under the ROC curve (AUC) calculations for efficacy prediction of the biomarkers
CD163 TSP1 IL-6 CD163/TSP-1/IL-6
Steroid response Dex 10−8 0.86 0.88 0.60 0.91
Dex 10−6 0.85 0.87 0.83 0.91
Steroid enhancement Dex 10−8 0.82 0.80 N/A# 0.86*
Dex 10−6 0.77 0.81 N/A# 0.96*
Steroid response and enhancement Dex 10−6 - - - 0.98
#Not applicable as the level of repression of DIMS0150 induced expression of IL-6 is analyzed.
*Calculation was performed including steroid response data of IL-6.
Bold number indicates highest efficacy prediction.
Table 6 Prediction of clinical response in DIMS0150
treated patients (n = 22) using CD163, TSP-1 and IL-6
Patient Steroid response Enhancing Steroid response
and enhancing
N01 1 0 0
N02 0 0 0
N03 0 0 0
N04 0 0 0
N05 0 0 0
N06 0 1 0
N07 0 0 0
N08 1 1 1
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http://www.biomedcentral.com/1471-230X/14/79reflecting the differences in the gene expression of these
three genes in responding and non-responding patients
(Figure 6). The healthy data points co-located with data
points from the non-responders suggesting that both
groups had a normal level of steroid sensitivity.
Table 6 shows the level of agreement between the pre-
diction of a clinical response and the actual clinical re-
sponse for each patient receiving the study drug.
Considering either the criteria for steroid resistance as
determined by the biomarkers or whether stimulation
with DIMS0150 was able to reverse the steroid resist-
ance in the assay, a correct prediction of 81% (17/21)
was obtained (Table 7). When using the combination of
both criteria namely, steroid resistance and enhancing
steroid sensitivity an overall correct prediction of 90.5%
(19/21) with a positive predictive value (PPV) of 90%
and a negative predictive value (NPV) of 91% was
achieved. Only two patients did not correlate with the
biomarker prediction, patient N08 who showed a posi-
tive result in the biomarker analysis but no clinical re-
sponse and patient R05 who was negative in theFigure 6 Classification analysis confirmed clinical responding
and non-responding patients as two distinct groups. Principal
components (pc) were calculated from the logarithms of the steroid
response data received from the qPCR analyses of CD163, TSP-1 and
IL-6 and pc1 against pc2 was plotted. (R) Clinical responder. (N) Clin-
ical non-responder. (H) Healthy volunteer. Circles present subjects
whose pc data are differing from their respective group.biomarker analysis but experienced a clinical response.
Two further patients, N04 and N05, received study drug
but were not on concomitant steroid treatment. They
were later excluded from the study as protocol violators.
Both of them were classified as being steroid sensitive in
the biomarker assay and were clinical non-responders.N09 0 0 0
N10 0 0 0
N11 0 0 0
N12 n.d. n.d. n.d.
R01 1 1 1
R02 1 0 1
R03 1 1 1
R04 1 1 1
R05 0 0 0
R06 1 1 1
R07 1 1 1
R08 1 1 1
R09 0 1 1
R10 1 1 1
(N) Clinical Non-responder defined as DIMS0150 treated patients with no
clinical response at week 1 and week 4.
(R) Clinical Responder defined as DIMS0150 treated patients with a clinical
response at week 1 and/or 4).
(0) Negative in classification analysis (i.e., steroid sensitive and/or not enhanced).
(1) Positive in classification analysis (i.e., steroid resistant and/or enhanced).
(n.d.) No data (no blood was received from patient for biomarker analysis).
Table 7 Summary of predictive potential of biomarkers CD163, TSP-1 and IL-6
Correct prediction Sensitivity Specificity PPV NPV
Steroid response 81% (17/21) 80% 82% 80% 82%
Enhancing 81% (17/21) 80% 82% 80% 82%
Steroid response and enhancing 90.5% (19/21) 90% 91% 90% 91%
(PPV) Positive predictive value.
(NPV) Negative predictive value.
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stratifying tool may have improved the clinical response
rate, we performed a retrospective analysis using the
study data. By removing all subjects that were neither
steroid resistant nor showed an enhancing effect to
DIMS0150 in the biomarker assay and retaining all
those that proved positive in both criteria, the response
rate in the treatment group would have increased from
32% to 60% (6/10) at wk1 and from 41% to 80% (8/10)
at wk4. These data demonstrate a clear usefulness in be-
ing able to identify patients most likely to benefit from
DIMS0150 treatment.DIMS0150 restores steroid sensitivity in vivo
In a case series of severe chronic active treatment refrac-
tory patients, treatment with DIMS0150 was provided
under named patient basis [15]. Here we had the oppor-
tunity to observe the effects of DIMS0150 treatment in a
subject receiving three doses with four weeks between
each dosing occasion. We noted an impressive response
with the subject in complete clinical remission at week
12 (defined as a CAI score of 0 and an endoscopic score
of 0) [37], 4 weeks after the third dose. Additionally, we
were able to collect blood before dosing and 12 weeks
after for the analysis of CD163, TSP-1 and IL-6 (Figure 7).
The analysis showed a strong reduced steroid response
indicating that the patient was steroid refractory at the
time of first dosing which is supported by the subject’s
treatment history of being resistant to a high course
treatment consisting of 100 mg Prednisolone/day for
5 days. After three administrations of DIMS0150, pa-
tient derived PBMCs responded similar to healthy con-
trols when incubated with Dexamethasone. This would
suggest that a restoration of sensitivity must have oc-
curred in vivo during DIMS0150 treatment. After a fur-
ther 14 weeks the patient experienced first disease
deteriorations (increase of the CAI score from 0 to 4)
and in light of the subject’s apparent improved steroid
sensitivity, the treating physician was advised to in-
crease the dose of GCS from 10 to 30 mg of Prednisol-
one/day. The patient regained complete remission
within a week suggesting that following a period of re-
sensitization to GCS, the patient was able to respond to
the elevated dose given.Discussion
Gastrointestinal disorders like UC can dramatically
affect the quality of life [38], and involves a life-long
clinical management of the disease focusing on the in-
duction and maintenance of remission. GCS remain the
treatment of choice of initial therapy but about a third
of the patients will fail to respond and further manage-
ment requires a comprehensive understanding of the pa-
tients and the potential risks and benefits of further
interventions making the disease course difficult to man-
age. The aim of the treatment with DIMS0150 is to help
the patients remain in the group of easier manageable
UC patients by restoring their steroid sensitivity.
The mechanisms behind steroid resistance are com-
plex and numerous cytokines have been implicated as
important factors. For example, Xystrakis and colleagues.
[18] could show that by restoring otherwise deficient
levels of IL-10 in steroid resistant asthmatics greatly im-
proved their steroid responsiveness. In a more recent
study performed with PBMCs derived from steroid re-
sistant UC patients, the authors could demonstrate that
addition of IL-10 to the PMBCs enhanced steroid sensi-
tivity, whereas neutralizing IL-10 through addition of
specific antibodies reduced steroid sensitivity [8].
Similar clinical observations have been demonstrated
using type I interferons. For example, steroid resistant
UC patients receiving daily intravenous injections of nat-
ural IFN-β experienced a rapid improvement of clinical
symptoms [39]. The ability of type I interferons to
modulate steroid sensitivity gained further support from
studies performed in steroid resistant asthmatics where
treatment with IFN-α dramatically improved symptoms
allowing their steroid dose to be tapered [19].
We could show that the TLR9 agonist DIMS0150 acts
as an immunomodulatory compound by inducing IL-10,
IL-6, type I interferons and IP-10 in vitro, the same cyto-
kines/chemokines implied to be important in regaining
steroid sensitivity. The induction of IP-10 in vivo in the
phase IIa study correlates well with the in vitro IP-10
analysis suggesting that treatment with DIMS0150 is
likely to induce the same steroid enhancing cytokines as
previously recorded.
The biomarker CD163 belongs to a superfamily of
cysteine-rich scavenger receptors (SRCR), several of
Figure 7 Biomarker assay confirms restoration of steroid sensitivity. A chronic active treatment refractory UC patient was treated on a
named patient basis with three doses of DIMS0150 with four weeks between dosing. Whole blood was collected prior to first dose and four
weeks following last dose (week 12) and PBMC incubated for 48 hrs in the absence or presence of Dexamethasone and/or DIMS0150. Following
incubation mRNA levels of IL-6 (A), CD163 (B) and TSP-1 (C) were analysed.
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CD163 is described to mediate anti-inflammatory effects
[41] and its expression is strongly induced by anti-
inflammatory mediators and GCS [20,42]. Interestingly,
some of these anti-inflammatory mediators that up-
regulate CD163 on mRNA level in monocytes and mac-
rophages are IL-6 and IL-10 [43-45], both of which are
shown to be induced by DIMS0150.
Thrombospondin-1 belongs functionally to a group of
diverse multidomain counteradhesive proteins influencing
endothelial cell behaviour [46-48]. It could be shown that
TSP-1 expression correlates with IL-10 expression in
colon cancer with significant lower mean vessel counts
suggesting that IL-10 stimulates expression of angiostatic
factors as TSP-1 [49], linking also the second biomarker
to a cytokine induced by DIMS0150. The identification of
these marker genes and their relation to DIMS0150 in-
duced cytokines are considered important factors in un-
derstanding how DIMS0150 restores steroid sensitivity.
To assess the clinical utility of CD163, TSP-1 and IL-
1RII as predictors of clinical response, a PoC phase IIa
study in steroid refractory or steroid dependent UC pa-
tients on concomitant steroid treatment was performed
and the results compared to those of the steroid sensitiv-
ity marker IL-6. Although this study was somewhat lim-
ited in size, it was nevertheless deemed sufficiently large
enough to provide a robust assessment of the bio-
markers. We hypothesized that DIMS0150 should en-
hance steroid sensitivity leading to improvements of
symptoms and a reduced disease activity score and that
prior analysis using the biomarker genes should enable a
prediction of clinical response. The clinical outcome of
the study showed that approximately half of the
DIMS0150 treated patients (10 of 22) responded to the
treatment and that this observation was very much in
line with the biomarker data obtained at the time of
screening. Both IL-6 and CD163 analysis strongly sug-
gested the presence of two groups of patients being in-
cluded in the study. One group demonstrated a clear
picture of steroid resistance and the other showed a ster-
oid response similar to healthy volunteers. Patients with
a reduced response to steroids as determined by CD163,
TSP-1 or IL-6 were statistically more likely to respond
to the DIMS0150 treatment. The predictive potential of
the biomarkers could be illustrated by classification ana-
lysis of the expression data compared to clinical re-
sponse or non-response following DIMS0150 treatment.
All three markers demonstrated a high potential as sur-
rogate markers for a DIMS0150 response with CD163
and TSP-1 being slightly more sensitive than IL-6 be-
cause of their ability to demonstrate the steroid re-
sensitizing effect of DIMS0150. As expected, the com-
bination of all three markers gave the best result with an
AUC of 0.98. This equates to a correct prediction ofclinical response in 90% (9/10) of patients classified as
being steroid refractory according to the biomarker
assay. Conversely, 91% (10/11) of patients whose steroid
sensitivity was comparable to healthy controls failed to
respond to DIMS0150 treatment. A possible interpret-
ation would be, patients classified with the biomarkers
as steroid refractory are indeed steroid refractory pa-
tients. By contrast, patients that show no difference to
healthy could be inferred as steroid dependent. The val-
idity of these interpretations can only be properly tested
through additional clinical studies where subjects are in-
cluded using the clinical definitions of steroid resistance
and dependence as given in the ECCO guidelines [10].
Regarding the special case patient who received three
doses of DIMS0150, the biomarker assay confirmed that
the patient was steroid refractory at time of first dosing
and classified as a potential responder to DIMS0150.
Upon treatment with DIMS0150, a pronounced clinical
response could be observed with the patient in complete
remission at week 12. Further biomarker analysis at
week 12 demonstrated that the patient most likely had
regained steroid sensitivity that could be confirmed by
treating an upcoming relapse successfully with GCS.
While we have consistently recorded a steroid re-
sensitizing effect for DIMS0150 in vitro, these in vivo
data provide for the first time, evidence for a shift to im-
proved steroid sensitivity in a steroid unresponsive pa-
tient following DIMS0150 treatment.
Based on these promising data, a placebo-controlled,
multiple dose, double-blind, randomized phase III clin-
ical study (NCT01493960) is currently on-going to as-
sess the efficacy and safety of DIMS0150 as an add-on to
current practice in chronic active treatment refractory
UC patients.
This study will also provide a unique opportunity to
gain further evidence for the observed in vivo shift in
steroid sensitivity following DIMS0150 treatment and
controlled steroid tapering combined with a long follow-
up phase will gather information about reaching and
length of steroid-free remission.
Conclusions
The work presented here demonstrates that the target
group of DIMS0150 are ulcerative colitis patients show-
ing a reduced steroid sensitivity and a clear utility of
using appropriate biomarkers for the selection of pa-
tients most likely to benefit from DIMS0150 treatment
has been illustrated. Using such an approach represents
a step towards a more personalized form of healthcare
and may aid physicians in making the most optimum
treatment choices for the patient.
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